Biotech Startups

Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy. Its lead candidate targets recurrent grade 3 IDH-mutant astrocytoma and other cancers with ODC overexpression.

4 investors

Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy. The Nasdaq-listed biotech (ticker ORTX) has commercialized therapies including Strimvelis and Libmeldy in Europe.

4 investors

Orchestra is a platform that unifies scientific, operational, and financial data into a single intelligent environment serving biotech and research teams. It functions as both a system of record and intelligence layer to enable data-driven decision-making and operational alignment.

4 investors

Ordaōs uses AI and deep learning through its Design Engine to design novel mini-proteins and protein binders such as nanobodies for drug discovery. The company serves pharmaceutical and biologics researchers, combining generative machine-learning models with wet-lab protein expression and characterization.

4 investors

Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases. The company works within the healthcare and pharmaceutical industry to address patient health challenges.

4 investors

OSSIO develops OSSIOfiber, a bio-integrative bone fixation implant material made from natural mineral fibers that provides stability during healing and integrates fully into bone over 18-24 months, avoiding permanent metal hardware. The implants are used in orthopedic surgical procedures such as hammertoe and other bone-healing treatments.

4 investors

Pandorum Technology develops tissue engineering and regenerative medicine products using proprietary stem cell and exosome platforms to address corneal dystrophies, lung disorders, and liver diseases. The company creates bio-engineered functional tissues through cell engineering, 3D printing, and cell-free therapies for medical research and therapeutic applications.

4 investors

PanTera develops actinium-225, a therapeutic radioisotope used in precision cancer treatment through radiotheranostics, serving oncology patients and pharmaceutical companies globally. The company operates a production facility in Belgium producing high-purity actinium-225 as an active pharmaceutical ingredient for personalized nuclear medicine treatments.

4 investors

PanTher develops targeted cancer therapeutics that deliver drugs directly to tumor sites at high concentrations over extended periods, aiming to improve clinical outcomes while reducing side effects. The platform is designed to be applicable across multiple therapeutic types for oncology treatment.

4 investors

Partillion generates cell-cell interaction data using Nanovials that co-localize cells in defined microenvironments to measure signaling, activation, binding, and other responses, with live-cell recovery via standard flow cytometry. Its platform serves researchers building biological models, discovering therapeutics such as T-cell engagers and antibodies, and profiling immune-target cell interactions.

4 investors

Peer AI builds AI-powered tools for drug development and clinical research, with a focus on medical writing and regulatory work. It serves life sciences and pharma organizations, combining generative AI with expertise in data protection and privacy.

4 investors

Phage Lab develops solutions to address bacterial outbreaks using a One Health approach, bringing together around 100 scientists and professionals from multiple disciplines in animal health and microbiology.

4 investors

PharmAbcine is a biotech company developing therapeutic antibodies, with a focus on immuno-oncology and antibody-based cancer treatments.

4 investors

Pharmacyclics, an AbbVie company, develops treatment options for cancer and immune-mediated diseases. It focuses on research and therapeutics for patients affected by these conditions.

4 investors

Phathom Pharmaceuticals is a pharmaceutical company that develops and markets prescription treatments, including VOQUEZNA (vonoprazan) for gastrointestinal conditions, in the U.S. market.

4 investors

PheroSyn produces pheromone lures designed to monitor and control agricultural pests through insect attractants. The products target farmers and agricultural professionals managing crop-damaging pest species.

4 investors

Phoenix Molecular Designs (PhoenixMD) is a biotechnology company developing targeted breast cancer therapeutics, including PMD-026, a first-in-class RSK2 inhibitor in Phase 2 clinical trials paired with a companion diagnostic. The company applies medicinal chemistry, computational modeling, and cancer biology to treat breast cancer and other cancers.

4 investors

PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.

4 investors

Picture Health develops AI tools that analyze routine radiology and pathology images to quantify biological properties of tumors for precision oncology. Its technology serves clinical development and translational science teams by producing imaging biomarkers from existing scans without additional tissue or lab tests.

4 investors

PinkDx is a diagnostics company developing tests, led by a leadership team spanning scientific, medical, and business functions.

4 investors

4 investors

Polymateria develops a proprietary plastic additive formulation that enables conventional plastics to biodegrade fully in natural environments without harming recycling streams. The technology, deployed as a masterbatch additive, allows plastics to remain functional during their service life, then convert to bioavailable waxes upon weathering before biodegrading within 1-2 years.

4 investors

Polymerize applies machine learning to polymer formulation, modeling the relationships between material structure, processing conditions, and resulting properties. The software suggests candidate formulations so teams run fewer physical experiments. It is used by R&D groups in materials and chemicals companies developing new products.

4 investors

Prenetics is a health company that operates in genetic testing and precision diagnostics and runs the consumer health supplement brand IM8, sold direct-to-consumer and through Amazon and social commerce channels. The company markets longevity and wellness products globally, including partnerships with athletes and sports organizations.

4 investors